Kinzalkomb

Hydrochlorothiazide and Telmisartan, the active ingredients in Kinzalkomb, are a thiazide diuretic and an angiotensin II receptor blocker presented as an oral tablet for systemic use. They are indicated for the treatment of hypertension in adult patients. The combination enhances blood pressure control by reducing fluid volume and blocking vasoconstrictive pathways, offering a convenient once‑daily regimen for patients requiring dual therapy.

GNH USA supplies Kinzalkomb as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide with rigorous quality assurance and regulatory adherence.

Kinzalkomb, a combination antihypertensive, acts on the renin‑angiotensin system and renal sodium handling to lower blood pressure. - Primary hypertension: lowers systolic and diastolic pressure in adults with essential hypertension. - Secondary hypertension: assists in blood pressure control when an underlying cause is identified but pharmacologic management is required. - Hypertension with fluid retention: combines diuretic and ARB effects to improve control in patients with volume overload.

Common Side Effects: - Dizziness - Headache - Increased urination - Fatigue

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Acute kidney injury - Hyperkalemia

Monitor blood pressure: ensure adequate control and avoid hypotension. Check electrolyte levels: especially potassium and sodium during therapy. Assess renal function: periodic testing recommended for patients with kidney disease. Review hepatic status: avoid in severe hepatic impairment. Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: risk of renal impairment. - Potassium‑sparing diuretics or supplements: may cause hyperkalemia. - NSAIDs: can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive blood pressure lowering. - Lithium: increased lithium levels, monitor for toxicity. - Antidiabetic drugs: may enhance hypoglycemic effect.